



August 1, 2017

Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017

- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -

NEW HAVEN, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- **Achillion Pharmaceuticals, Inc.** (Nasdaq:ACHN) today announced that it plans to report second quarter 2017 financial results on Tuesday, August 8, 2017, after the markets close. Achillion will also host a conference call and live webcast to discuss these results and to provide an update on the Company's factor D inhibitor platform, including Achillion's novel first-in-class oral compound, ACH-4471. The conference call will be held at 4:05 p.m. ET.

A live audio webcast of the call and accompanying slides will be accessible at <http://www.achillion.com> or <http://ir.achillion.com>. Please connect to Achillion's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. To participate in the conference call, please dial (866) 205-4820 in the U.S. or (419) 386-0004 for international callers.

A replay of the webcast will be available for 30 days on <http://www.achillion.com>. Alternatively, a telephonic replay of the conference call will be available starting at 8:00 p.m. ET on August 8, 2015, through 7:05 p.m. ET on August 12, 2017 by dialing (855) 859-2056 or (404) 537-3406. The replay passcode is 63792663.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at <http://www.achillion.com>.

Investors & Media:

Glenn Schulman

Achillion Pharmaceuticals, Inc.

Tel. (203) 752-5510

gschulman@achillion.com